Hu Kejia, Callen David Frederick, Li Jiayuan, Zheng Hong
1 Sichuan University, Chengdu, Sichuan, People's Republic of China.
2 University of Adelaide, Adelaide, South Australia, Australia.
Integr Cancer Ther. 2018 Jun;17(2):217-225. doi: 10.1177/1534735417712007. Epub 2017 Jun 7.
Studies have shown that vitamin D could have a role in breast cancer survival; however, the evidence of the relationship between patients' vitamin D levels and their survival has been inconsistent. This meta-analysis explores possible dose-response relationships between vitamin D levels and overall survival by allowing for differences in vitamin D levels among populations of the various studies. Studies relating vitamin D (25-OH-D [25-hydroxyvitamin D]) levels in breast cancer patients with their survival were identified by searching PubMed and Embase. A pooled HR (hazard ratio) comparing the highest with the lowest category of circulating 25-OH-D levels were synthesized using the Mantel-Haenszel method under a fixed-effects model. A two-stage fixed-effects dose-response model including both linear (a log-linear dose-response regression) and nonlinear (a restricted cubic spline regression) models were used to further explore possible dose-response relationships. Six studies with a total number of 5984 patients were identified. A pooled HR comparing the highest with the lowest category of circulating 25-OH-D levels under a fixed-effects model was 0.67 (95% confidence interval = 0.56-0.79, P < .001). Utilizing a dose-response meta-analysis, the pooled HR for overall survival in breast cancer patients was 0.994 (per 1 nmol/L), P < .001. At or above a 23.3 nmol/L threshold, for a 10 nmol/L, 20 nmol/L, or 25 nmol/L increment in circulating 25-OH-D levels, the risk of breast cancer overall mortality decreased by 6%, 12%, and 14%, respectively. There was no significant nonlinearity in the relationship between overall survival and circulating 25-OH-D levels. Our findings suggest that there is a highly significant linear dose-response relationship between circulating 25-OH-D levels and overall survival in patients with breast cancer. However, better designed prospective cohort studies and clinical trials are needed to further confirm these findings.
研究表明维生素D可能在乳腺癌患者的生存中发挥作用;然而,关于患者维生素D水平与其生存率之间关系的证据并不一致。本荟萃分析通过考虑不同研究人群中维生素D水平的差异,探讨维生素D水平与总生存率之间可能的剂量反应关系。通过检索PubMed和Embase数据库,确定了有关乳腺癌患者维生素D(25-羟维生素D[25-OH-D])水平与其生存率关系的研究。在固定效应模型下,使用Mantel-Haenszel方法合成了比较循环25-OH-D水平最高类别与最低类别的合并风险比(HR)。采用包括线性(对数线性剂量反应回归)和非线性(受限立方样条回归)模型的两阶段固定效应剂量反应模型,进一步探讨可能的剂量反应关系。共确定了6项研究,涉及5984例患者。在固定效应模型下,比较循环25-OH-D水平最高类别与最低类别的合并HR为0.67(95%置信区间=0.56-0.79,P<.001)。采用剂量反应荟萃分析,乳腺癌患者总生存的合并HR为0.994(每1 nmol/L),P<.001。在23.3 nmol/L阈值及以上,循环25-OH-D水平每增加10 nmol/L、20 nmol/L或25 nmol/L,乳腺癌总体死亡风险分别降低6%、12%和14%。总生存率与循环25-OH-D水平之间的关系不存在显著的非线性。我们的研究结果表明,循环25-OH-D水平与乳腺癌患者的总生存率之间存在高度显著的线性剂量反应关系。然而,需要设计更完善的前瞻性队列研究和临床试验来进一步证实这些发现。